NCT07535008Recruiting
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 10 Apr 2026
- Start date
- 12 May 2026
- Primary completion date
- 30 Apr 2028
- Lead sponsor
- Fred Hutchinson Cancer Center
- NCT number
- NCT07535008
What you commit to
- Study type: Interventional
- Planned participants: 45
- From 12 May 2026 to the primary completion date, 30 Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis
Other
- Edentulous state
- Bone marrow as graft source
- Use of anti-thymocyte globulin (ATG) in conditioning
Who the study is looking for
- Age ≥ 18 years old
- T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed
- One of the following HCT donor types:
- 9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor
- Cord blood
- Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)
- Ability to understand and sign a written informed consent document (or legal representative)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium Coordinator of this site? Confirm its status | Seattle | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.